AbbVie vs Novo Nordisk A/S: Business Model & Financial Comparison 2026
AbbVie · Healthcare / Drug Manufacturers - General·Novo Nordisk A/S · Healthcare / Drug Manufacturers - General
Financial Comparison
| Metric | ABBVAbbVie | NVONovo Nordisk A/S |
|---|---|---|
| Market Cap | $388.43B | $169.29B |
| Revenue (TTM) | $61.16B | $309.06B |
| Revenue Growth | 10.0% | -7.6% |
| Gross Margin | 71.6% | 82.4% |
| Operating Margin | 34.1% | 44.5% |
| Net Margin | 6.9% | 33.1% |
| Return on Equity | 6225.0% | 60.7% |
| P/E (Trailing) | 92.7x | 10.7x |
| P/E (Forward) | 13.6x | 11.4x |
| Free Cash Flow | $18.34B | $376.9M |
| Cash | $5.26B | $26.96B |
| Total Debt | $68.40B | $130.96B |
Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.
Business Model Comparison
AbbVie
AbbVie Inc. stands as a leading company in Healthcare. Generating $61.16 billion in annual revenue (growing 10.0% year-over-year) and carrying a market capitalization of $410.83 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, AbbVie Inc. continues to execute on a multi-year strategic vision that balances growth investment wit…
Full AbbVie analysis →Novo Nordisk A/S
Novo Nordisk A/S stands as a leading company in Healthcare. Generating $309.06 billion in annual revenue (growing -7.6% year-over-year) and carrying a market capitalization of $173.66 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Novo Nordisk A/S continues to execute on a multi-year strategic vision that balances growth inv…
Full Novo Nordisk A/S analysis →SWOT Analysis Comparison
Strengths
AbbVie
- With a market capitalization of $410.83B, AbbVie Inc. is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access that sma
- AbbVie Inc.'s gross margin of 71.6% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 34.1% demonstrates disciplin
- A return on equity of 6225.0% demonstrates that AbbVie Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
Novo Nordisk A/S
- With a market capitalization of $173.66B, Novo Nordisk A/S is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access tha
- Novo Nordisk A/S's gross margin of 82.4% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 44.5% demonstrates disc
- A return on equity of 60.7% demonstrates that Novo Nordisk A/S generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
Weaknesses
AbbVie
- In the Drug Manufacturers - General sector, larger competitors with greater economies of scale can exert pricing pressure and outspend AbbVie Inc. on marketing, R&D, and distribution — limiting the co
- Revenue concentration in core markets or customer segments creates vulnerability to localized downturns, regulatory changes, or shifts in customer preferences. Diversification remains an ongoing strat
Novo Nordisk A/S
- Novo Nordisk A/S's debt-to-equity ratio of 67.5 indicates meaningful financial leverage. Total debt stands at $130.96B against $26.96B in cash and equivalents.
- Year-over-year revenue declined 7.6%, raising questions about demand for Novo Nordisk A/S's core offerings and requiring management to articulate a credible recovery path.
Opportunities
AbbVie
- AbbVie Inc. operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this env
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for AbbVie
- With $5.26B in cash and strong free cash flow generation, AbbVie Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.
Novo Nordisk A/S
- Novo Nordisk A/S operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in thi
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Novo No
- With $26.96B in cash and strong free cash flow generation, Novo Nordisk A/S is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.
Threats
AbbVie
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. AbbVie Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scen
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on AbbVie Inc.'s busin
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Novo Nordisk A/S
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Novo Nordisk A/S's revenue is not fully insulated from macroeconomic cycles, and a recession
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Novo Nordisk A/S's
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Compare any 2–4 companies with live data
The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.
Open Comparison ToolAbbVie vs Novo Nordisk A/S: FAQ
- Is AbbVie bigger than Novo Nordisk A/S?
- By market capitalization, AbbVie is larger at $388.43B vs Novo Nordisk A/S's $169.29B.
- Which has better profit margins — AbbVie or Novo Nordisk A/S?
- Novo Nordisk A/S has higher net profit margins (33.1%) compared to AbbVie (6.9%). Gross and operating margins are compared in the table above.
- What sectors do AbbVie and Novo Nordisk A/S operate in?
- AbbVie operates in the Healthcare sector (Drug Manufacturers - General). Novo Nordisk A/S operates in the Healthcare sector (Drug Manufacturers - General).
- How does AbbVie's revenue compare to Novo Nordisk A/S's?
- AbbVie generates $61.16B in annual revenue (TTM) while Novo Nordisk A/S generates $309.06B. Novo Nordisk A/S is the larger company by revenue as of 2026.